Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Induction treatment with XELOX plus bevacizumab in locally advanced rectal adenocarcinoma (Phase II)
2006-005499-42Phase 2Active
- Sponsor
- ACROSS Group
- Start
- Jan 2007
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab, capecitabine and oxaliplatin in rectal adenocarcinoma and colon cancer, sponsored by ACROSS Group. Primary endpoint: pathological complete response rate. Started Jan 2007; status: active.
02
Drugs
bevacizumabcapecitabineoxaliplatin
03
Conditions
rectal adenocarcinomacolon cancer
Beyond the preview
Go deeper on 2006-005499-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-005499-42.